Genzyme takeover, how to benefit?

Discussion in 'Stocks' started by brendan.lee25, Oct 4, 2010.

  1. Genzyme is currently trading at a premium to the $69 per share cash offer:

    However it sounds as if "Sanofi will eventually have to raise its offer, already rejected by Genzyme a month ago" and that a price somewhere in the range of $75 per share is more likely.

    Thus at a price of $71 per share right now is Genzyme a buy or sell?

    Could a derivative such as a future or an option be a safer buy than common stock?